Loading...
Fennec Pharmaceuticals Inc.
FENC•NASDAQ
HealthcareBiotechnology
$8.43
$0.53(6.71%)
Fennec Pharmaceuticals Inc. (FENC) Company Profile & Overview
Explore Fennec Pharmaceuticals Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Fennec Pharmaceuticals Inc. (FENC) Company Profile & Overview
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
SectorHealthcare
IndustryBiotechnology
CEOMr. Jeffrey S. Hackman
Contact Information
Company Facts
32 Employees
IPO DateSep 15, 2017
CountryUS
Actively Trading